Cytokinetics, Incorporated
CYTK
शेयरों में रैंक
#2258
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on... Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
शेयर मूल्य
$64.11
अंतिम समन्वयन: 2026-10-20
मार्केट कैप
$8.91B
बदलाव (1 दिन)
2.34%
बदलाव (1 वर्ष)
10.96%
देश
US
व्यापार Cytokinetics, Incorporated (CYTK)
श्रेणी
Healthcare
Cytokinetics, Incorporated (CYTK) के लिए कमाई
Jun 2026 में कमाई TTM: $-894.00M
Cytokinetics, Incorporated की नवीनतम वित्तीय रिपोर्टों के अनुसार, कंपनी की वर्तमान कमाई $-894.00M है। 2023 में कंपनी ने $-526.24M की कमाई की, जो 2022 की कमाई $-388.96M के की तुलना में कमी है। इस पृष्ठ पर दिखाई गई कमाई ब्याज और कर से पहले की कमाई है, जिसे EBIT कहा जाता है।
Cytokinetics, Incorporated के लिए कमाई का इतिहास 2000 से 2026 तक
प्रत्येक वर्ष के अंत में कमाई
| वर्ष | कमाई | परिवर्तन |
|---|---|---|
| 2026 (TTM) | $-894.00M | 51.65% |
| 2024 | $-589.53M | 12.03% |
| 2023 | $-526.24M | 35.30% |
| 2022 | $-388.96M | 80.65% |
| 2021 | $-215.31M | 69.15% |
| 2020 | $-127.29M | 4.60% |
| 2019 | $-121.69M | 14.49% |
| 2018 | $-106.29M | -16.83% |
| 2017 | $-127.79M | -876.70% |
| 2016 | $16.45M | -143.87% |
| 2015 | $-37.50M | 156.05% |
| 2014 | $-14.65M | -56.56% |
| 2013 | $-33.72M | -13.58% |
| 2012 | $-39.02M | -18.48% |
| 2011 | $-47.86M | -3.24% |
| 2010 | $-49.46M | -300.30% |
| 2009 | $24.69M | -143.80% |
| 2008 | $-56.37M | 15.30% |
| 2007 | $-48.89M | -14.39% |
| 2006 | $-57.12M | 35.18% |
| 2005 | $-42.25M | 13.59% |
| 2004 | $-37.20M | 0.00% |
| 2003 | 0.00 | 0.00% |
| 2002 | 0.00 | 0.00% |
| 2001 | 0.00 | 0.00% |
| 2000 | 0.00 | 0.00% |
समान कंपनियों या प्रतियोगियों की कमाई
| कंपनी | कमाई | कमाई में अंतर | देश |
|---|---|---|---|
| $5.27B | -690.03% |
US
|
|
| $-3.09B | 245.30% |
US
|
|
| $-4.02B | 349.24% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -318.19% |
NL
|
